Omeros Overview
- Year Founded
-
1994
- Status
-
Public
- Employees
-
198
- Stock Symbol
-
OMER
- Investments
-
2
- Share Price
-
$3.74
- (As of Thursday Closing)
Omeros General Information
Description
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Contact Information
Website
www.omeros.comCorporate Office
- The Omeros Building
- 201 Elliott Avenue West
- Seattle, WA 98119
- United States
Corporate Office
- The Omeros Building
- 201 Elliott Avenue West
- Seattle, WA 98119
- United States
Omeros Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $3.74 | $3.68 | $0.92 - $5.68 | $217M | 57.9M | 343K | -$2.35 |
Omeros Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 240,478 | 236,134 | 263,567 | 700,176 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (181,183) | (159,498) | (162,389) | (172,217) |
| Net Income | (140,043) | (117,813) | 47,417 | 194,235 |
| Total Assets | 356,314 | 378,269 | 590,969 | 419,268 |
| Total Debt | 212,599 | 236,458 | 342,023 | 347,839 |
Omeros Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Omeros Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Omeros Comparisons
Industry
Financing
Details
000000
0000 0
Omeros Competitors (57)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ProMIS Neurosciences | Corporation | Toronto, Canada | 0 | 000.00 | 000000000 | 000.00 |
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | 000 | 00.000 | 000000000 | 00.000 |
| Ambrx | Formerly PE-Backed | San Diego, CA | 00 | 00000 | 000000&0 | 00000 |
| Metabolic Solutions Development | Venture Capital-Backed | Kalamazoo, MI | 00 | 0000 | 000000 - 000 | 0000 |
| LifeMine | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 00000000000 | 00000 |
Omeros Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Omeros Patents
Omeros Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240228499-A1 | Masp-2 inhibitors and methods of use | Pending | 30-Nov-2022 | 0000000000 | |
| US-20240228666-A1 | Therapeutic methods and uses for antibodies to human masp-3 | Pending | 02-Nov-2022 | 000000000 | |
| US-20230416406-A1 | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease | Pending | 10-Mar-2022 | 000000000 | |
| US-20230265215-A1 | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof | Pending | 10-Dec-2021 | 000000000 | |
| US-20240101709-A1 | Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof | Pending | 10-Dec-2021 | C07K16/40 | 0 |
Omeros Executive Team (28)
| Name | Title | Board Seat |
|---|---|---|
| Gregory Demopulos MD | Founder, Chief Executive Officer, Board of Directors & Chairman | |
| George Gaitanaris Ph.D | Chief Scientific Officer and Vice President, Science | |
| Nadia Dac | Chief Commercial Officer | |
| Catherine Melfi Ph.D | Executive & Vice President | |
| Bruce Bobzien | Sr. Sourcing Recruiter |
Omeros Board Members (10)
| Name | Representing | Role | Since |
|---|---|---|---|
| Arnold Hanish | Self | Board Member | 000 0000 |
| Gregory Demopulos MD | Omeros | Founder, Chief Executive Officer, Board of Directors & Chairman | 000 0000 |
| Kurt Zumwalt | Self | Board Member | 000 0000 |
| Leroy Hood Ph.D | Self | Board Member | 000 0000 |
| Peter Demopulos MD | Self | Board Member | 000 0000 |
Omeros Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Omeros Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Patobios (GPCR Assay Technology) | 22-Nov-2010 | 0000000000 | 000.00 | Biotechnology | 0000000 0 |
| Nura (USA) | 07-Sep-2006 | Merger/Acquisition | 00000 | Drug Discovery | 0000000 0 |
Omeros ESG
Risk Overview
Risk Rating
Updated September, 27, 2023
36.75 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 16,009
Rank
Percentile
Pharmaceuticals
Industry
00 of 909
Rank
Percentile
Pharmaceuticals
Subindustry
00 of 446
Rank
Percentile
Omeros FAQs
-
When was Omeros founded?
Omeros was founded in 1994.
-
Who is the founder of Omeros?
Gregory Demopulos MD is the founder of Omeros.
-
Who is the CEO of Omeros?
Gregory Demopulos MD is the CEO of Omeros.
-
Where is Omeros headquartered?
Omeros is headquartered in Seattle, WA.
-
What is the size of Omeros?
Omeros has 198 total employees.
-
What industry is Omeros in?
Omeros’s primary industry is Biotechnology.
-
Is Omeros a private or public company?
Omeros is a Public company.
-
What is Omeros’s stock symbol?
The ticker symbol for Omeros is OMER.
-
What is the current stock price of Omeros?
As of 12-Sep-2024 the stock price of Omeros is $3.74.
-
What is the current market cap of Omeros?
The current market capitalization of Omeros is $217M.
-
Who are Omeros’s competitors?
ProMIS Neurosciences, SAGE Therapeutics, Ambrx, Metabolic Solutions Development, and LifeMine are some of the 57 competitors of Omeros.
-
What is Omeros’s annual earnings per share (EPS)?
Omeros’s EPS for 12 months was -$2.35.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
